Arecor Therapeutics PLC - biopharmaceutical company based in Little Chesterford, England - Announces hiring of David Ellam as interim chief financial officer, effective immediately. Ellam was most recently CFO at Sixfold Bioscience Ltd from July 2023 to September this year, before which he worked as a finance strategy consultant for KBio. Prior to this he was CFO at Silence Therapeutics PLC from 2016 to 2019, at Juvenescence Ltd for one year, then at Wondr Medical from June to December 2022. Ellam succeeds Susan Lowther, Arecor’s first CFO, who announced her resignation ‘to pursue new opportunities’ in April.

Chief Executive Officer Sarah Howell comments: ‘David is a highly experienced finance executive whose life sciences knowledge and broad financial expertise will be highly valuable in supporting the business moving forward including as we continue to execute our strategic initiatives to drive shareholder value.’

Current stock price: 75.50 pence, down 0.1% on Monday afternoon in London

12-month change: down 59%

Copyright 2024 Alliance News Ltd. All Rights Reserved.